Researchers found that Smad1 was conformationally modified by Pin1 specific binding, leading to the failure of Smurf1 interaction, thereby stabilizing Smad1 protein against ubiquitination degradation and sustaining its activation, which enabled Pin to be a candidate therapeutic target in many skeletal diseases [81]. This evidence concerns the gene SMAD1 and bone disorder.